AU2002340139A1 - Inhibitors of the egf receptor for the treatment of thyroid cancer - Google Patents

Inhibitors of the egf receptor for the treatment of thyroid cancer

Info

Publication number
AU2002340139A1
AU2002340139A1 AU2002340139A AU2002340139A AU2002340139A1 AU 2002340139 A1 AU2002340139 A1 AU 2002340139A1 AU 2002340139 A AU2002340139 A AU 2002340139A AU 2002340139 A AU2002340139 A AU 2002340139A AU 2002340139 A1 AU2002340139 A1 AU 2002340139A1
Authority
AU
Australia
Prior art keywords
inhibitors
treatment
thyroid cancer
egf receptor
egf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002340139A
Other languages
English (en)
Inventor
James Alexander Fagin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2002340139A1 publication Critical patent/AU2002340139A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2002340139A 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer Abandoned AU2002340139A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32788001P 2001-10-09 2001-10-09
US60/327,880 2001-10-09
PCT/US2002/032195 WO2003030908A2 (en) 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer

Publications (1)

Publication Number Publication Date
AU2002340139A1 true AU2002340139A1 (en) 2003-04-22

Family

ID=23278480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002340139A Abandoned AU2002340139A1 (en) 2001-10-09 2002-10-08 Inhibitors of the egf receptor for the treatment of thyroid cancer

Country Status (5)

Country Link
US (1) US20040191254A1 (https=)
EP (1) EP1435959A2 (https=)
JP (1) JP2005531488A (https=)
AU (1) AU2002340139A1 (https=)
WO (1) WO2003030908A2 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60137273D1 (de) * 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
ATE508747T1 (de) * 2003-03-10 2011-05-15 Eisai R&D Man Co Ltd C-kit kinase-hemmer
EP1493445A1 (en) * 2003-07-04 2005-01-05 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of stress-induced ligand-dependent EGFR activation
WO2005039588A2 (en) * 2003-10-22 2005-05-06 Novartis Ag Methods for determining the risk of developing liver and lung toxicity
US7683172B2 (en) * 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
JP2007515400A (ja) * 2003-11-28 2007-06-14 ノバルティス アクチエンゲゼルシャフト タンパク質キナーゼ依存性疾患の処置におけるジアリール尿素誘導体
AU2005283422C1 (en) * 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
EP1925941B1 (en) * 2005-08-01 2012-11-28 Eisai R&D Management Co., Ltd. Method for prediction of the efficacy of vascularization inhibitor
WO2007015578A1 (ja) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を検定する方法
CN101316590B (zh) * 2005-11-07 2011-08-03 卫材R&D管理有限公司 血管生成抑制剂和c-kit激酶抑制剂的组合使用
WO2007061130A1 (ja) * 2005-11-22 2007-05-31 Eisai R & D Management Co., Ltd. 多発性骨髄腫に対する抗腫瘍剤
RU2448708C3 (ru) * 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
EP2044939A1 (en) * 2006-06-29 2009-04-08 Eisai R&D Management Co., Ltd. Therapeutic agent for liver fibrosis
CN101511793B (zh) * 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
CN101600694A (zh) * 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
AU2009210098B2 (en) * 2008-01-29 2013-06-13 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
JP5767122B2 (ja) 2009-03-11 2015-08-19 アルデア バイオサイエンシズ，インコーポレイティド 特定の癌の治療のためのｒｄｅａ１１９／ｂａｙ８６９７６６を含む組み合わせ医薬
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
WO2011162343A1 (ja) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
SI2902029T1 (sl) * 2012-09-25 2018-11-30 Chugai Seiyaku Kabushiki Kaisha Inhibitor ret
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EP2997377B1 (en) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
EP3624800A4 (en) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. TREATMENT OF HEPATOCELLULAR CARCINOMA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747598A (en) * 1990-01-16 1998-05-05 Mobil Oil Corporation Epoxidized solid elastomeric copolymers
EP0531472B1 (en) * 1991-03-06 2003-08-13 MERCK PATENT GmbH Humanized monoclonal antibodies
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
MX9800215A (es) * 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
WO1997049798A1 (en) * 1996-06-27 1997-12-31 University Of Helsinki Glial cell line-derived neurotrophic factor regulation of ureteric budding and growth, and of enteric innervation
AU6887698A (en) * 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6987113B2 (en) * 1997-06-11 2006-01-17 Sugen, Inc. Tyrosine kinase inhibitors
AR033680A1 (es) * 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
GB0031080D0 (en) * 2000-12-20 2001-01-31 Novartis Ag Organic compounds
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US20040191254A1 (en) 2004-09-30
EP1435959A2 (en) 2004-07-14
WO2003030908A2 (en) 2003-04-17
JP2005531488A (ja) 2005-10-20
WO2003030908A3 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2002340139A1 (en) Inhibitors of the egf receptor for the treatment of thyroid cancer
PL375532A1 (en) Benzimidazol-1-yl-thiophene compounds for the treatment of cancer
AU2002360766A1 (en) Methods for cancer imaging
EP1372736A4 (en) PREPARATIONS AGAINST CANCER FORMATION
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002252456A1 (en) Combination treatment of pancreatic cancer
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU2002328952A1 (en) Irinotecan for treatment of cancer
AUPR395801A0 (en) Antibodies against cancer
AU2000258650A1 (en) 2-piperidone compounds for the treatment of cancer
AU2002305333A1 (en) Compounds and methods for the modulation of cd154
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
AU2001290165A1 (en) Components of canola for the treatment of cancer
AU2002320098A1 (en) Dye-azide compounds for dual phototherapy
AU8322401A (en) Indole compounds useful for the treatment of cancer
AU2002353739A1 (en) Therapeutic compounds
AU2002308642A1 (en) Methods for treating cancer
HUP0402341A3 (en) Compositions containing thiazol-2-ylamines for the treatment of cancer
AU2003223538A1 (en) Methods for the treatment of cancer
AU2002304883A1 (en) Device for the treatment of tumours
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2002359916A1 (en) Preventives/remedies for cancer
AU2000263936A1 (en) Substance p analogs for the treatment of cancer
AU2002351382A1 (en) Combination cancer therapy
AU2002366272A1 (en) Edg-receptor agonist for the treatment of hypertension

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase